MedWatch

FDA expands Dupixent indication, EU application to follow

Sanofi and Regeneron’s eczema treatment Dupixent is now approved for use in babies as young as six months old in the US.

Photo: Rodrigo Cid

Eczema treatment Dupixent can now be used by an even wider group of patients in the US, as the FDA has approved an application to extend the use of the drug.

The indication expansion means that the treatment can now be given to children aged between six months and five years old suffering from moderate to severe atopic dermatitis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs